I don't know if today's market reflects someone knowing that what you're saying is actually the case, or if it's purely speculation about results.

Frankly, I'd be thrilled just to know the drug was working well with psoriasis, anything beyond that could be icing on the cake. The key IMHO is real data which includes photographic proof of improvements in the conditions of patients with the disease.

I'm still unsure such results will be discussed before the next quarterly report, which I expect mid November. I really would like them to schedule a quarterly webcast where they could truly speak with the investment community. Even if the trial wasn't concluded, they could at least reveal it's expansion officially, and why it was done. Clearly I believe the clinicians were thrilled with product safety, and recommended further development to determine product efficacy. Remember, the trial is supposed to be double blind, so while the company should be able to sense the enthusiasm of the clinicians, formally they won't have seen the data until the trial concludes.

Gary